313 related articles for article (PubMed ID: 28106545)
1. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.
Akyol M; Alacacioglu A; Demir L; Kucukzeybek Y; Yildiz Y; Gumus Z; Kara M; Salman T; Varol U; Taskaynatan H; Oflazoglu U; Bayoglu V; Tarhan MO
Cancer Biomark; 2017; 18(4):441-449. PubMed ID: 28106545
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
Akyol M; Demir L; Alacacioglu A; Ellidokuz H; Kucukzeybek Y; Yildiz Y; Gumus Z; Bayoglu V; Yildiz I; Salman T; Varol U; Kucukzeybek B; Demir L; Dirican A; Sutcu R; Tarhan MO
Chemotherapy; 2016; 61(2):57-64. PubMed ID: 26571369
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
[TBL] [Abstract][Full Text] [Related]
4. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Hong N; Yoon HG; Seo DH; Park S; Kim SI; Sohn JH; Rhee Y
Eur J Cancer; 2017 Sep; 82():103-114. PubMed ID: 28651157
[TBL] [Abstract][Full Text] [Related]
5. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
Francini G; Petrioli R; Montagnani A; Cadirni A; Campagna S; Francini E; Gonnelli S
Br J Cancer; 2006 Jul; 95(2):153-8. PubMed ID: 16835585
[TBL] [Abstract][Full Text] [Related]
6. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
Montagnani A; Gonnelli S; Cadirni A; Caffarelli C; Del Santo K; Pieropan C; Campagna MS; Montomoli M; Petrioli R; Nuti R
Eur J Intern Med; 2008 Dec; 19(8):592-7. PubMed ID: 19046724
[TBL] [Abstract][Full Text] [Related]
7. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
[TBL] [Abstract][Full Text] [Related]
8. Serum apelin levels and body composition changes in breast cancer patients treated with an aromatase inhibitor.
Salman T; Demir L; Varol U; Akyol M; Oflazoglu U; Yildiz Y; Taskaynatan H; Cengiz H; Guvendi G; Kucukzeybek Y; Alacacioglu A; Tarhan O
J BUON; 2016; 21(6):1419-1424. PubMed ID: 28039702
[TBL] [Abstract][Full Text] [Related]
9. [Postoperative changes in serum lipid levels of breast cancer and adjuvant chemotherapy].
Morimoto K; Koh M
Gan To Kagaku Ryoho; 2004 Oct; 31(10):1517-24. PubMed ID: 15508443
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Chlebowski RT; Schottinger JE; Shi J; Chung J; Haque R
Cancer; 2015 Jul; 121(13):2147-55. PubMed ID: 25757699
[TBL] [Abstract][Full Text] [Related]
11. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
12. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
13. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Esteva FJ; Hortobagyi GN
Breast; 2006 Jun; 15(3):301-12. PubMed ID: 16230014
[TBL] [Abstract][Full Text] [Related]
14. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
15. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
17. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
18. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer.
Joensuu H; Holli K; Oksanen H; Valavaara R
Breast Cancer Res Treat; 2000 Oct; 63(3):225-34. PubMed ID: 11110056
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
Pan K; Chlebowski RT
Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
[TBL] [Abstract][Full Text] [Related]
20. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
Ward JH
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
